The next era will be from the release of the gene

In wirelessness health summit Last week, David Liu, the pioneer who liberates genes at Harvard University and says later this year his laboratory is planning to report a single genes editing strategy that can treat many unrelated diseases. He is called poor therapeutic genes of the disease.

“This seems to be a kind of madness, but there is in reality a good reason for the molecular biology well,” he told the audience in Boston.

Genetics remedies are currently developed for many rare genetic diseases and heirs. Treating genes, called CasvishIt has been approved and commercially available to treat sickle cell disease and related blood disorder called a third beta. Earlier this year, KJ MULDONON, a baby who was born with a deadly genetic disease often caused by the accumulation of ammonia in his blood, with a Treating custom genes– Medical first.

These treatments work by targeting specific mutations related to these diseases. But it can be expensive for development and must be designed for a specific patient. Sometimes, these sick inhabitants can be very young, as in the case of the child KJ. His condition, called CPS1 deficiency, affects only one of 1.3 million live births.

Liu imagines a future in which the release of genes can be used on various various diseases, regardless of the device or tissues that affect it or its genetic cause. He says that this type of simplified strategy is required because it is collective, there are many rare diseases, and it will be practical to design treatments for each of them. Global genes, a rare disease invitation organization, estimate that there are at least 10,000 rare diseases affecting more than 400 million people worldwide.

Photo: Voti Phili

“The genetic disease as a whole is not very rare. It is actually more widespread than cancer or HIV/AIDS,” Liu said. “We urgently need these methods to treat the radical cause of these genetic diseases directly.”